BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29962813)

  • 1. Hepatitis C virus infection in children in the era of direct-acting antiviral.
    Pawlowska M; Sobolewska-Pilarczyk M; Domagalski K
    World J Gastroenterol; 2018 Jun; 24(24):2555-2566. PubMed ID: 29962813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.
    D'Ambrosio R; Degasperi E; Aghemo A; Fraquelli M; Lampertico P; Rumi MG; Facchetti F; Grassi E; Casazza G; Rosenberg W; Bedossa P; Colombo M
    PLoS One; 2016; 11(6):e0155967. PubMed ID: 27304619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy.
    Li H; Huang MH; Jiang JD; Peng ZG
    World J Gastroenterol; 2018 Dec; 24(47):5297-5311. PubMed ID: 30598575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
    Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
    Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
    J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.
    Stasi C; Piluso A; Arena U; Salomoni E; Montalto P; Monti M; Boldrini B; Corti G; Marra F; Laffi G; Milani S; Zignego AL
    World J Gastroenterol; 2015 Mar; 21(10):3013-9. PubMed ID: 25780300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of hepatitis C patients with decompensated liver disease.
    Hsu CS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):679-88. PubMed ID: 26782619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment.
    Kim JH; Kim MN; Han KH; Kim SU
    Liver Int; 2015 Apr; 35(4):1103-15. PubMed ID: 24976523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating paediatric hepatitis C in the era of direct-acting antiviral agents.
    Alqahtani SA; Colombo MG
    Liver Int; 2021 Jun; 41(6):1189-1200. PubMed ID: 33533543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-invasive diagnostic methods of fibrosis in chronic hepatitis C virus infection: their role in treatment indication, follow-up and assessment of prognosis].
    Pár A; Vincze Á; Pár G
    Orv Hetil; 2015 May; 156(21):855-61. PubMed ID: 26038993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of liver biopsy in the era of direct-acting antivirals.
    Gonzalez HC; Jafri SM; Gordon SC
    Curr Gastroenterol Rep; 2013 Feb; 15(2):307. PubMed ID: 23319086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
    Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
    Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.
    Kawagishi N; Suda G; Kimura M; Maehara O; Yamada R; Tokuchi Y; Kubo A; Kitagataya T; Shigesawa T; Suzuki K; Ohara M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Sakamoto N
    Sci Rep; 2021 Apr; 11(1):9207. PubMed ID: 33911145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era.
    Murphy N; O'Mahony B; Flanagan P; Noone D; White B; Bergin C; Norris S; Thornton L;
    Haemophilia; 2017 Sep; 23(5):712-720. PubMed ID: 28752601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
    Li T; Qu Y; Guo Y; Wang Y; Wang L
    Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.
    Song AT; Sobesky R; Vinaixa C; Dumortier J; Radenne S; Durand F; Calmus Y; Rousseau G; Latournerie M; Feray C; Delvart V; Roche B; Haim-Boukobza S; Roque-Afonso AM; Castaing D; Abdala E; D'Albuquerque LA; Duclos-Vallée JC; Berenguer M; Samuel D
    World J Gastroenterol; 2016 May; 22(18):4547-58. PubMed ID: 27182164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.